ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Idenix: 89% of Patients in Hep C Trial Arm Achieved Viral Suppression

By Ben Fox Rubin Biopharmaceutical firm Idenix Pharmaceuticals Inc. (IDIX) has provided some results from an ongoing Phase 2b study of its lead hepatitis C drug, IDX184, showing positive suppression of the virus. Shares jumped 15% after hours Tuesday to $10.79, as the company's stock often moves sharply following reports related to its or its competitors' hepatitis C drugs. As of the market close, the shares were up 26% so far this year. Idenix is among a handful of companies scrabbling to develop a marketable all-oral Hepatitis C drug, with demand for the treatment expected to be worth billions of dollars a year. Gilead Sciences Inc. (GILD) is a main competitor of Idenix in the race develop such a drug; it spent $11 billion to buy Pharmasset this year, in part to obtain its lead hepatitis C drug candidate, GS-7977. In the Idenix study, Idenix used a mix of its IDX184 with older medications interferon and ribavirin. In all, 31 patients were enrolled and 18 reached extended rapid virologic response, which is when the virus becomes undetectable at four weeks of treatment and again at 12 weeks of treatment. Of those 18 patients, nine were given additional treatments for 12 more weeks. All but one of them achieved sustained virologic response, or undetectable traces of the virus, a month after treatment ended. The other nine patients and those who didn't reach extended rapid virologic response are continuing a regimen of 36 weeks of treatment. Write to Ben Fox Rubin at ben.rubin@dowjones.com

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
01/30/201518:58:13MARKET SNAPSHOT: Gasoline 'tax Cut' In Focus On Energy, Consumer-based...
01/30/201516:32:24AbbVie Hepatitis C Drug Predictions Disappoint -- Update
01/15/201500:11:45India Rejects Gilead Patent Bid
01/15/201500:05:25India Rejects Gilead Patent Bid for Sovaldi Hepatitis C Treatment...
01/08/201517:22:44AbbVie Predicts Sharp Increase in Earnings
01/04/201519:30:08Drug Prices to Get More Expensive -- Corporate Outlook
12/29/201420:26:24MARKET SNAPSHOT: S&P 500 Rises To Record, But Dow Snaps 7-day...
12/29/201420:23:11MARKET SNAPSHOT: S&P 500, Dow On Pace For Record Closes
12/29/201419:35:44MARKET SNAPSHOT: S&P 500 Hits Another Record As Stocks Edge Up
12/24/201412:21:07MARKET SNAPSHOT: U.S. Stocks Inch Higher As Santa Rally Stays...
12/24/201411:03:29MARKET SNAPSHOT: U.S. Stocks Inch Higher As Santa Stays Jolly
12/24/201411:02:54MARKET SNAPSHOT: U.S. Stocks Inch Higher; Oil Drops
12/22/201417:36:19U.S. Hot Stocks: Hot Stocks to Watch
12/11/201407:47:33GlaxoSmithKline Seeks Variation on Authorization for Ambrisentan
12/10/201416:11:30Philadelphia Agency Sues Gilead Over Price Of Hepatitis Drug--Update
12/10/201414:16:17Philadelphia Transit Agency Sues Gilead, Claiming Sovaldi Price-Gouging
10/29/201415:01:09Gilead: Buy the Dip -- Barron's
10/28/201406:48:25Biotech Bull Intact But Showing Signs of Age -- Barron's
10/27/201416:09:31Biotech Bull Intact But Showing Signs of Age
10/26/201405:18:37MARKET SNAPSHOT: Energy, Health Care Earnings To Dominate Week

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad